PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021

А virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer (HR+ HER2- aBC) with the PIK3CA mutation using target drug alpelisib was held on April 23, 2021. Oncologists from France and Russia discussed the significance of the PIK3C...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Editorial Board
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2021
Materias:	hormone receptor positive her2-negative advanced breast cancer pik3ca mutation pi3k inhibitor alpelisib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/e25c25c15e6444e58fb7e756bf7334f1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e25c25c15e6444e58fb7e756bf7334f1
record_format	dspace
spelling	oai:doaj.org-article:e25c25c15e6444e58fb7e756bf7334f12021-11-30T16:55:01ZPIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 20211815-14341815-144210.26442/18151434.2021.2.200923https://doaj.org/article/e25c25c15e6444e58fb7e756bf7334f12021-08-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/77894/58478https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442А virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer (HR+ HER2- aBC) with the PIK3CA mutation using target drug alpelisib was held on April 23, 2021. Oncologists from France and Russia discussed the significance of the PIK3CA mutation, the necessity and methods of its identification. They also shared information and exchanged experience of using alpelisib to treat patients who had previously received a CDK4/6 inhibitor and were resistant to endocrine therapy. Using the example of a clinical case, the experts also discussed the issues of prevention and correction of adverse events.Editorial BoardIP Habib O.N.articlehormone receptor positive her2-negative advanced breast cancerpik3ca mutationpi3k inhibitoralpelisibNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 23, Iss 2, Pp 269-274 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	hormone receptor positive her2-negative advanced breast cancer pik3ca mutation pi3k inhibitor alpelisib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	hormone receptor positive her2-negative advanced breast cancer pik3ca mutation pi3k inhibitor alpelisib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Editorial Board PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021
description	А virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer (HR+ HER2- aBC) with the PIK3CA mutation using target drug alpelisib was held on April 23, 2021. Oncologists from France and Russia discussed the significance of the PIK3CA mutation, the necessity and methods of its identification. They also shared information and exchanged experience of using alpelisib to treat patients who had previously received a CDK4/6 inhibitor and were resistant to endocrine therapy. Using the example of a clinical case, the experts also discussed the issues of prevention and correction of adverse events.
format	article
author	Editorial Board
author_facet	Editorial Board
author_sort	Editorial Board
title	PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021
title_short	PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021
title_full	PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021
title_fullStr	PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021
title_full_unstemmed	PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021
title_sort	pik3ca mutation: changing the paradigm of hr+ her2-negative metastatic breast cancer therapy. review of the novartis pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent her2-negative advanced breast cancer with a pik3ca gene mutation. april 23, 2021
publisher	IP Habib O.N.
publishDate	2021
url	https://doaj.org/article/e25c25c15e6444e58fb7e756bf7334f1
work_keys_str_mv	AT editorialboard pik3camutationchangingtheparadigmofhrher2negativemetastaticbreastcancertherapyreviewofthenovartispharmasatellitesymposiumheldaspartofavirtualforumdedicatedtothediagnosisandtreatmentofpatientswithhormonedependenther2negativeadvancedbreastcancerwithapik3cag
_version_	1718406475767873536

Ejemplares similares